
Opinion|Videos|August 15, 2024
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly comment on the recent FDA accelerated approval granted to lisocabtagene maraleucel (liso-cel) based on the findings from TRANSCEND CLL 004.
- How may this impact future treatment practices? In which patients may you consider this treatment approach?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5




































